Bicycle Therapeutics plc Schedules 2024 Annual General Meeting

Ticker: BCYC · Form: DEF 14A · Filed: Apr 15, 2024 · CIK: 1761612

Sentiment: neutral

Topics: AGM, Proxy Statement, Shareholder Vote, Corporate Governance, Bicycle Therapeutics

TL;DR

**Bicycle Therapeutics plc is holding its 2024 Annual General Meeting on May 16, 2024, in New York, urging shareholders to vote.**

AI Summary

BICYCLE THERAPEUTICS plc (BCYC) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. The 2024 Annual General Meeting (AGM) for Bicycle Therapeutics plc will be held on May 16, 2024, at 9:00 a.m. EDT (2:00 p.m. London time). The meeting will take place at the offices of Cooley LLP, located at 55 Hudson Yards, New York, NY 10001. Shareholders are encouraged to vote as soon as possible using the provided proxy card or other voting options. The company is incorporated and registered in England and Wales with Company No. 11036004. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 15, 2024.

Why It Matters

For investors and stakeholders tracking BICYCLE THERAPEUTICS plc, this filing contains several important signals. The AGM is a key event for shareholders to exercise their voting rights on company matters, including the election of directors and other corporate governance issues. Shareholder participation is crucial for the company's governance and demonstrates investor engagement with the company's strategic direction.

Risk Assessment

Risk Level: BCYC — BICYCLE THERAPEUTICS plc shows moderate risk based on this filing. The filing is a routine proxy statement for an annual general meeting, containing standard disclosures and no new material financial or strategic information.

Analyst Insight

Shareholders should review the proxy materials carefully and vote their shares prior to the May 16, 2024 AGM to ensure their voice is heard on corporate governance matters.

Key Numbers

Key Players & Entities

FAQ

When did BICYCLE THERAPEUTICS plc file this DEF 14A?

BICYCLE THERAPEUTICS plc filed this Proxy Statement (DEF 14A) with the SEC on April 15, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by BICYCLE THERAPEUTICS plc (BCYC).

Where can I read the original DEF 14A filing from BICYCLE THERAPEUTICS plc?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BICYCLE THERAPEUTICS plc.

What are the key takeaways from BICYCLE THERAPEUTICS plc's DEF 14A?

BICYCLE THERAPEUTICS plc filed this DEF 14A on April 15, 2024. Key takeaways: The 2024 Annual General Meeting (AGM) for Bicycle Therapeutics plc will be held on May 16, 2024, at 9:00 a.m. EDT (2:00 p.m. London time).. The meeting will take place at the offices of Cooley LLP, located at 55 Hudson Yards, New York, NY 10001.. Shareholders are encouraged to vote as soon as possible using the provided proxy card or other voting options..

Is BICYCLE THERAPEUTICS plc a risky investment based on this filing?

Based on this DEF 14A, BICYCLE THERAPEUTICS plc presents a moderate-risk profile. The filing is a routine proxy statement for an annual general meeting, containing standard disclosures and no new material financial or strategic information.

What should investors do after reading BICYCLE THERAPEUTICS plc's DEF 14A?

Shareholders should review the proxy materials carefully and vote their shares prior to the May 16, 2024 AGM to ensure their voice is heard on corporate governance matters. The overall sentiment from this filing is neutral.

How does BICYCLE THERAPEUTICS plc compare to its industry peers?

Bicycle Therapeutics plc is a biopharmaceutical company focused on developing novel medicines. This filing relates to its annual shareholder meeting, a standard corporate governance event.

Are there regulatory concerns for BICYCLE THERAPEUTICS plc?

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

Risk Factors

Industry Context

Bicycle Therapeutics plc is a biopharmaceutical company focused on developing novel medicines. This filing relates to its annual shareholder meeting, a standard corporate governance event.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

  1. Review the proxy statement for details on proposals and voting procedures.
  2. Vote your shares before the May 16, 2024 deadline.
  3. Attend the AGM or appoint a proxy to vote on your behalf.

Key Dates

Year-Over-Year Comparison

This is a routine DEF 14A filing for the upcoming Annual General Meeting and does not represent a change from previous reporting cycles in terms of new financial data or strategic shifts.

Filing Stats: 4,961 words · 20 min read · ~17 pages · Grade level 11 · Accepted 2024-04-15 16:05:15

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 36 TRANSACTIONS WITH RELATED PERSONS 39 DIRECTOR REMUNERATION 41 EXECUTIVE OFFICERS OF THE COMPANY 44

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 46 PAY VERSUS PERFORMANCE 53 EQUITY COMPENSATION PLAN INFORMATION 57 ADDITIONAL INFORMATION 58 ANNEX A – DIRECTORS' REMUNERATION REPORT A-1 ANNEX B – NEW ARTICLES OF ASSOCIATION B-1 Table of Contents BICYCLE THERAPEUTICS PLC Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, United Kingdom (Incorporated and Registered in England and Wales with Registered Company No. 11036004) PROXY STATEMENT FOR THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 16, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING We have sent you this proxy statement and the enclosed form of proxy because the Board of Directors (the " Board ") of Bicycle Therapeutics plc is soliciting your proxy to vote at our annual general meeting of shareholders (the " AGM "). As used in this proxy statement, references to " we ," " us ," " our " and the " Company " refer to Bicycle Therapeutics plc. The Notice of 2024 Annual General Meeting, this proxy statement, the form of proxy, our U.K. statutory annual accounts and reports for the year ended December 31, 2023 (" 2023 U.K. Annual Report ") and our annual report on Form 10-K for the year ended December 31, 2023 (the " Annual Report on Form 10-K ," and collectively with the Notice of 2024 Annual General Meeting, this proxy statement, the 2023 U.K. Annual Report and the form of proxy, " Proxy Materials "), will be made available to our ordinary shareholders of record for the first time on or about April 15, 2024. While this proxy statement is made available to our ordinary shareholders of record, this document will also be sent to holders of American Depositary Shares (" ADSs ") for the first time on or about April 15, 2024 and contains information relevant to holders of ADSs. In addition, we have provided brokers, dealers, bankers, and their nominees, at our expense, with copies of the Proxy Materials so that our record holders can supply these

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing